ABSTRACT
OBJECTIVE@#To evaluate the diagnostic value of endostatin (ES), vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in both serum and pleural effusion of lung cancer patients.@*METHODS@#Levels of ES, VEGF and CEA in 52 malignant pleural effusion due to lung cancer and 50 patients with non-malignant disease were measured by using sandwich enzyme-linked immunosorbent assay and microparticle enzyme immunoassay.@*RESULTS@#The ES, VEGF and CEA levels in pleural effusion and serum, and their ratio (F/S) were higher in lung cancer group than that in benign group, and the differences were statistically significant (P<0.05). The diagnostic efficiency of ES+VEGF for lung cancer was superior to either single detection. The diagnostic efficiency of ES+VEGF+CEA was superior to either ES+VEGF or ES+CEA.@*CONCLUSIONS@#The results suggest that ES, VEGF and CEA might be useful in the differentiation between benign and malignant pleural effusion due to lung cancer. In comparison with either single determination of concentration in serum or pleural fluid, the combined detection of two or three markers is of important clinical significance in the diagnosis of lung cancer.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Biomarkers, Tumor , Carcinoembryonic Antigen , Early Detection of Cancer , Endostatins , Lung Neoplasms , Blood , Diagnosis , Pleura , Chemistry , Pleural Effusion , Metabolism , Vascular Endothelial Growth Factor AABSTRACT
<p><b>OBJECTIVE</b>To investigate the prognostic factors for non-small cell lung cancer(NSCLC)in patients under 40 years of age.</p><p><b>METHODS</b>The clinicopathological data of 148 young patients with NSCLC were retrospectively analyzed. Kaplan-Meier and Cox regression analyses were used to analyze the relationship between prognostic factors and survival time.</p><p><b>RESULTS</b>The patients were followed-up for 6 - 148 months, and the follow-up rate was 100%. In the whole group, 122 patients died and 26 cases were surviving. The 1-, 3- and 5-year survival rates were 54.7%, 10.4% and 5.6%, respectively. The median survival time (MST) was 14.7 months. Kaplan-Meier analysis showed that Karnofsky performance status (KPS), clinical stage, treatment modality and serum CEA were related with prognosis (P < 0.05). Multivariate analysis indicated that KPS, clinical stage, treatment modality and serum CEA were independent prognostic factors (P < 0.05).</p><p><b>CONCLUSIONS</b>KPS, CEA, clinical stage and treatment modalities are independent prognostic factors in young NSCLC patients.</p>
Subject(s)
Adolescent , Adult , Female , Humans , Male , Young Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoembryonic Antigen , Blood , Carcinoma, Non-Small-Cell Lung , Blood , Drug Therapy , Pathology , Radiotherapy , General Surgery , Combined Modality Therapy , Follow-Up Studies , Karnofsky Performance Status , Lung Neoplasms , Blood , Drug Therapy , Pathology , Radiotherapy , General Surgery , Neoplasm Staging , Pneumonectomy , Methods , Proportional Hazards Models , Retrospective Studies , Survival RateABSTRACT
<p><b>BACKGROUND</b>Can single-agent maintenance therapy be considered as an ideal strategy for non-small cell lung cancer (NSCLC) treatment to achieve prolonged survival and tolerated toxicity? A systematic review and meta-analysis was performed to elucidate this issue.</p><p><b>METHODS</b>The electronic databases were searched for RCTs comparing single-agent maintenance therapy with placebo, best support care or observation. The required data for estimation of response, survival and toxicity were extracted from the publications and the combined data were calculated.</p><p><b>RESULTS</b>Eleven RCTs involving 3686 patients were identified. We found a statistically significant higher probability of tumor response for patients with maintenance therapy versus control patients (OR: 2.80, 95%CI: 2.15 - 3.64). Patients receiving maintenance therapy had significantly longer progression-free survival (PFS) (HR: 0.67, 95%CI: 0.62 - 0.71) and overall survival (OS) (HR: 0.84, 95%CI: 0.78 - 0.90). However, maintenance therapy was associated with more severe toxicities (OR: 6.45, 95%CI: 4.61 - 9.01).</p><p><b>CONCLUSION</b>In patients with advanced NSCLC, the use of single-agent maintenance therapy is associated with higher response rate and significantly prolongs PFS and OS despite of the risk of additional toxicity.</p>
Subject(s)
Humans , Antineoplastic Agents , Therapeutic Uses , Carcinoma, Non-Small-Cell Lung , Drug Therapy , Mortality , Disease-Free Survival , Lung Neoplasms , Drug Therapy , Mortality , Publication BiasABSTRACT
Objective To observe the short-term efficacy of treating the tumorous airway obstruction by placing net stents following high-frequency electrocautery via fiberoptic bronchoscope.Methods 14 patients of lung cancer with airway obstruction had undergone the tumor burning excision by high-frequency electrocautery via fiberoptic bronchoscope and placed net stents , then to observe the clinical efficiency.Results 14 patients of lung cancer with airway obstruction all revealed better efficacies, obviously improving Karnofsky scores and pulmonary function, and no evident complication was found.Conclusion Placing net stents following high-frequency electrocautery via fiberoptic bronchoscope can cure efficiently the tumorous airway obstruction, and have popular value.